Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males of any race, between 18 and 55 years of age, inclusive, at Screening.~2. Body mass index between 18.5 and 29.9 kg/m2, inclusive, at Screening and Check-in.~3. Total body weight between 60 and 95 kg, inclusive, at Screening and Check-in.~4. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital nonhaemolytic hyperbilirubinemia \[eg, Gilbert's syndrome\] is acceptable) at Screening or Check-in as assessed by the Investigator (or designee).~5. Relevant clinical laboratory evaluations of haematology, coagulation, urinalysis and clinical chemistry within the following ranges at Screening and Check in. A single repeat test will be allowed at each timepoint.~   * Absolute neutrophil count ≥1.5 × 109 L~  * Platelet count ≥100 × 109 L~  * Haemoglobin \>10 g/dl~  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ ULN~  * Alkaline phosphatase (ALP) ≤1.5 × ULN~  * Total bilirubin ≤ 1.5 ULN with direct bilirubin \<20% in case of total bilirubin \> ULN~  * Blood urea nitrogen ≤1.5 × ULN~  * Creatinine \<132.63 µmol/L~  * Serum albumin: ≥35 g/L~  * Total cholesterol ≤ 7.75 mmol/L~  * Triglycerides ≤ 3.42 mmol/L~  * Creatine kinase (CK) ≤3 × ULN~  * International normalised ratio (INR) 0.8 to 1.3~  * Urine dipstick for proteinuria \<2+~6. Systolic blood pressure ≥90 mmHg and \<140 mmHg and diastolic blood pressure ≥50 mmHg and \<90 mmHg at Screening and Check in.~7. Subjects agree to use contraception.~8. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions. Subjects must have signed an informed consent before any study-related procedure or evaluation is performed.~Exclusion Criteria:~1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).~2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).~3. Any current or recent history of active infections, including localised infections. (Within 2 months prior Screening Visit for any serious infection which requires hospitalization or intravenous anti-infective, and within 14 days prior Screening Visit for any active infection which requires oral treatment).~4. History of, or planned surgery, including suturing, dental surgery or wound dehiscence within 30 days of dosing, or within 30 days of the last study visit.~5. Presence of a nonhealing wound or fracture.~6. Known history of clinically significant essential hypertension, orthostatic hypotension, fainting spells or blackouts for any reason, cardiac failure or history of thromboembolic conditions.~7. Medically significant dental disease or dental neglect, with signs and/or symptoms of local or systemic infection that would likely require a dental procedure during the course of the study.~8. Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to Check-in, and/or positive urinary test for alcohol or drugs of abuse at Screening or Check in.~9. History of bleeding disorders or protein C, protein S, and/or factor V Leiden deficiency.~10. History of clinically significant haemorrhage, epistaxis, GI bleeding, haemorrhoids and/or haemoptysis.~11. History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel disease, diverticular disease, or any fistulae.~12. Alcohol consumption of \>24 units per week. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.~13. Positive hepatitis panel, positive human immunodeficiency test. Subjects whose results are compatible with prior immunisation and not infection may be included at the discretion of the Investigator.~14. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to Check-in, or within 5 half lives of the investigational drug used in the study.~15. Use or intend to use slow-release medications/products considered to still be active within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).~16. Use or intend use of any prescription medications/ nonprescription products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator or designee.~17. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).~18. Have received a live or attenuated vaccine from 3 months prior to Screening or have the intention to receive a vaccine during the study.~19. Intend to travel to a region where a vaccination will be required due to endemic disease within 3 months of dosing.~20. Previous treatment with an anti VEGF antibody or any other protein or antibody targeting the VEGF receptor.~21. Use of tobacco- or nicotine-containing products within 1 year prior to Check-in, or positive cotinine test upon Screening or Check-in.~22. Receipt of blood products within 60 days prior to Check-in.~23. Donation of blood from 90 days prior to Screening, plasma from 14 days prior to Screening, or platelets from 42 days prior to Screening.~24. Poor peripheral venous access.~25. History of abnormal peripheral sensation including paraesthesia and/or numbness in arms and/or legs.~26. Have previously completed or withdrawn from this study or any other study investigating bevacizumab, and/or have previously received bevacizumab.~27. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.~28. Vulnerable subjects (e.g. persons kept in detention).~29. Subjects who are study site employees or immediate family members of a study site or Mabxience employee.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- MB02 (Bevacizumab Biosimilar) (Type: EXPERIMENTAL): Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
- EU approved Avastin® (Type: ACTIVE_COMPARATOR): Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
- US licenced Avastin® (Type: ACTIVE_COMPARATOR): Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete